These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 2800585)
1. Pharmacoeconomic research and clinical trials: concepts and issues. Bootman JL; Larson LN; McGhan WF; Townsend RJ DICP; 1989 Sep; 23(9):693-7. PubMed ID: 2800585 [TBL] [Abstract][Full Text] [Related]
2. Pharmacoeconomics: an emerging discipline. Letizia C Qual Assur; 1995 Mar; 4(1):68-74. PubMed ID: 8520866 [TBL] [Abstract][Full Text] [Related]
3. Establishing value through pharmacoeconomics: the emerging third objective in clinical trials. Boyer JG; Pathak DS Top Hosp Pharm Manage; 1994 Jan; 13(4):1-10. PubMed ID: 10130679 [TBL] [Abstract][Full Text] [Related]
4. Pharmacoeconomics. Ahuja J; Gupta M; Gupta AK; Kohli K Natl Med J India; 2004; 17(2):80-3. PubMed ID: 15141600 [TBL] [Abstract][Full Text] [Related]
5. Pharmacoeconomic analysis in Saudi Arabia: an overdue agenda item for action. Al-Jazairi AS; Al-Qadheeb NS; Ajlan A Ann Saudi Med; 2011; 31(4):335-41. PubMed ID: 21808106 [TBL] [Abstract][Full Text] [Related]
8. Pitfalls associated with commonly used methods for pharmacoeconomic analyses. Klepser DG Pharmacotherapy; 2002 Feb; 22(2 Pt 2):35S-38S. PubMed ID: 11837545 [TBL] [Abstract][Full Text] [Related]
9. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria]. Führlinger S Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765 [TBL] [Abstract][Full Text] [Related]
10. Guidelines for performing a pharmacoeconomic analysis. Jolicoeur LM; Jones-Grizzle AJ; Boyer JG Am J Hosp Pharm; 1992 Jul; 49(7):1741-7. PubMed ID: 1621734 [TBL] [Abstract][Full Text] [Related]
11. The rationale of pharmacoeconomic analysis in rheumatologic indications. Turchetti G; Scalone L; Della Casa Alberighi O; Mosca M; Montella S; Cortesi PA; Mantovani LG Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S64-71. PubMed ID: 23072796 [TBL] [Abstract][Full Text] [Related]
19. Institutional formularies: the relevance of pharmacoeconomic analysis to formulary decisions. Lipsy RJ Pharmacoeconomics; 1992 Apr; 1(4):265-81. PubMed ID: 10147017 [TBL] [Abstract][Full Text] [Related]
20. Economic evaluations during early (phase II) drug development: a role for clinical trial simulations? Hughes DA; Walley T Pharmacoeconomics; 2001; 19(11):1069-77. PubMed ID: 11735674 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]